Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 21498485.
- Also identified by DOI 10.3899/jrheum.101249.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine the timing for safe reduction of mycophenolate mofetil (MMF) dose during remission-maintenance therapy of proliferative lupus nephritis. The study population consisted of 44 patients evaluated retrospectively; MMF dose was empirically tapered in 18/44 patients until the latest observation. Patients reducing MMF ≤ 18 months after remission/complete remission had a 6.8-fold/6.3-fold higher risk of relapse compared to those taking a stable dose (p = 0.001, p = 0.011, respectively). Reducing MMF later than 18 months was not associated with increased relapse rates. Reducing MMF > 1.5 years after remission/complete remission seems to warrant drug tapering without increased risk of disease flare in proliferative lupus nephritis.
Medical subject headings
- Immunosuppressive Agents
- Lupus Nephritis
- Mycophenolic Acid